Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma

Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. We reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (st...

Full description

Saved in:
Bibliographic Details
Published inThe European respiratory journal Vol. 59; no. 4; p. 2100768
Main Authors Busby, John, Matthews, John G., Chaudhuri, Rekha, Pavord, Ian D., Hardman, Timothy C., Arron, Joseph R., Bradding, Peter, Brightling, Christopher E., Choy, David F., Cowan, Douglas C., Djukanovic, Ratko, Hanratty, Catherine E., Harrison, Tim W., Holweg, Cecile T., Howarth, Peter H., Fowler, Stephen J., Lordan, James L., Mansur, Adel H., Menzies-Gow, Andrew, Niven, Robert M., Robinson, Douglas S., Walker, Samantha M., Woodcock, Ashley, Heaney, Liam G.
Format Journal Article
LanguageEnglish
Published England European Respiratory Society 01.04.2022
Subjects
Online AccessGet full text
ISSN0903-1936
1399-3003
1399-3003
DOI10.1183/13993003.00768-2021

Cover

Abstract Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. We reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (study participant), multicentre, parallel group 48-week clinical study comparing biomarker-directed treatment adjustment with standard care in severe asthma. Of 1572 treatment advisories (291 participants), instructions were followed in 1377 cases (87.6%). Patients were more likely to follow advice to remain on treatment (96.7%) than to either reduce (70.3%) or increase (67.1%) their treatment, with 64% of patients following all treatment advice. Multivariate analysis associated belonging to an ethnic minority group (OR 3.10, 95% CI 1.68-5.73) and prior study medication changes (two or more changes: OR 2.77, 95% CI 1.51-5.10) with failure to follow treatment advice. In contrast, emergency room attendance in the prior year (OR 0.54, 95% CI 0.32-0.92) was associated with following treatment advice. The largest effect was seen with transition onto or off oral corticosteroids (OR 29.28, 95% CI 16.07-53.36) when compared with those requested to maintain treatment. Centre was also an important determinant regarding the likelihood of patients to follow treatment advice. Belonging to an ethnic minority group and multiple prior treatment adjustments were associated with not following HCP treatment advice. Patients also responded differently to HCP advice across UK specialist centres. These findings have implications for the generalisability of models of care in severe asthma and require further focused studies.
AbstractList Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management.BACKGROUNDUnderstanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management.We reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (study participant), multicentre, parallel group 48-week clinical study comparing biomarker-directed treatment adjustment with standard care in severe asthma.METHODSWe reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (study participant), multicentre, parallel group 48-week clinical study comparing biomarker-directed treatment adjustment with standard care in severe asthma.Of 1572 treatment advisories (291 participants), instructions were followed in 1377 cases (87.6%). Patients were more likely to follow advice to remain on treatment (96.7%) than to either reduce (70.3%) or increase (67.1%) their treatment, with 64% of patients following all treatment advice. Multivariate analysis associated belonging to an ethnic minority group (OR 3.10, 95% CI 1.68-5.73) and prior study medication changes (two or more changes: OR 2.77, 95% CI 1.51-5.10) with failure to follow treatment advice. In contrast, emergency room attendance in the prior year (OR 0.54, 95% CI 0.32-0.92) was associated with following treatment advice. The largest effect was seen with transition onto or off oral corticosteroids (OR 29.28, 95% CI 16.07-53.36) when compared with those requested to maintain treatment. Centre was also an important determinant regarding the likelihood of patients to follow treatment advice.RESULTSOf 1572 treatment advisories (291 participants), instructions were followed in 1377 cases (87.6%). Patients were more likely to follow advice to remain on treatment (96.7%) than to either reduce (70.3%) or increase (67.1%) their treatment, with 64% of patients following all treatment advice. Multivariate analysis associated belonging to an ethnic minority group (OR 3.10, 95% CI 1.68-5.73) and prior study medication changes (two or more changes: OR 2.77, 95% CI 1.51-5.10) with failure to follow treatment advice. In contrast, emergency room attendance in the prior year (OR 0.54, 95% CI 0.32-0.92) was associated with following treatment advice. The largest effect was seen with transition onto or off oral corticosteroids (OR 29.28, 95% CI 16.07-53.36) when compared with those requested to maintain treatment. Centre was also an important determinant regarding the likelihood of patients to follow treatment advice.Belonging to an ethnic minority group and multiple prior treatment adjustments were associated with not following HCP treatment advice. Patients also responded differently to HCP advice across UK specialist centres. These findings have implications for the generalisability of models of care in severe asthma and require further focused studies.CONCLUSIONSBelonging to an ethnic minority group and multiple prior treatment adjustments were associated with not following HCP treatment advice. Patients also responded differently to HCP advice across UK specialist centres. These findings have implications for the generalisability of models of care in severe asthma and require further focused studies.
Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. We reviewed patient choice to follow HCP advice to adjust asthma treatment in a UK-based randomised, controlled, single-blind (study participant), multicentre, parallel group 48-week clinical study comparing biomarker-directed treatment adjustment with standard care in severe asthma. Of 1572 treatment advisories (291 participants), instructions were followed in 1377 cases (87.6%). Patients were more likely to follow advice to remain on treatment (96.7%) than to either reduce (70.3%) or increase (67.1%) their treatment, with 64% of patients following all treatment advice. Multivariate analysis associated belonging to an ethnic minority group (OR 3.10, 95% CI 1.68-5.73) and prior study medication changes (two or more changes: OR 2.77, 95% CI 1.51-5.10) with failure to follow treatment advice. In contrast, emergency room attendance in the prior year (OR 0.54, 95% CI 0.32-0.92) was associated with following treatment advice. The largest effect was seen with transition onto or off oral corticosteroids (OR 29.28, 95% CI 16.07-53.36) when compared with those requested to maintain treatment. Centre was also an important determinant regarding the likelihood of patients to follow treatment advice. Belonging to an ethnic minority group and multiple prior treatment adjustments were associated with not following HCP treatment advice. Patients also responded differently to HCP advice across UK specialist centres. These findings have implications for the generalisability of models of care in severe asthma and require further focused studies.
Belonging to a minority ethnic group, multiple prior medication changes, being treated at a specific clinical centre, introduction of systemic corticosteroids and increased asthma symptoms were associated with resistance to asthma treatment modification https://bit.ly/3gYb66S
Author Chaudhuri, Rekha
Fowler, Stephen J.
Pavord, Ian D.
Walker, Samantha M.
Choy, David F.
Howarth, Peter H.
Lordan, James L.
Woodcock, Ashley
Djukanovic, Ratko
Matthews, John G.
Menzies-Gow, Andrew
Brightling, Christopher E.
Mansur, Adel H.
Cowan, Douglas C.
Busby, John
Niven, Robert M.
Hardman, Timothy C.
Robinson, Douglas S.
Heaney, Liam G.
Arron, Joseph R.
Hanratty, Catherine E.
Holweg, Cecile T.
Bradding, Peter
Harrison, Tim W.
AuthorAffiliation 5 Niche Science & Technology Ltd, London, UK
3 NHS Greater Glasgow and Clyde Health Board, Gartnavel General Hospital and University of Glasgow, Glasgow, UK
4 Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, The University of Oxford, Oxford, UK
10 Nottingham Respiratory NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
12 The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK
15 University College Hospitals NHS Foundation Trust, London, UK
1 Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
9 School of Clinical and Experimental Sciences, University of Southampton, NIHR Southampton Biomedical Research Centre, Southampton, UK
7 Dept of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK
14 Royal Brompton and Harefield NHS Foundation Trust, London, UK
11 Division of Infection, Immunity and Respi
AuthorAffiliation_xml – name: 5 Niche Science & Technology Ltd, London, UK
– name: 9 School of Clinical and Experimental Sciences, University of Southampton, NIHR Southampton Biomedical Research Centre, Southampton, UK
– name: 15 University College Hospitals NHS Foundation Trust, London, UK
– name: 2 23 and Me, Sunnyvale, CA, USA
– name: 3 NHS Greater Glasgow and Clyde Health Board, Gartnavel General Hospital and University of Glasgow, Glasgow, UK
– name: 12 The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK
– name: 4 Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, The University of Oxford, Oxford, UK
– name: 7 Dept of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK
– name: 8 NHS Greater Glasgow and Clyde, Stobhill Hospital, Glasgow, UK
– name: 11 Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, and Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK
– name: 1 Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
– name: 10 Nottingham Respiratory NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
– name: 13 University of Birmingham and Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
– name: 6 Genentech Inc., South San Francisco, CA, USA
– name: 16 Asthma UK and British Lung Foundation Partnership, London, UK
– name: 14 Royal Brompton and Harefield NHS Foundation Trust, London, UK
Author_xml – sequence: 1
  givenname: John
  surname: Busby
  fullname: Busby, John
– sequence: 2
  givenname: John G.
  surname: Matthews
  fullname: Matthews, John G.
– sequence: 3
  givenname: Rekha
  surname: Chaudhuri
  fullname: Chaudhuri, Rekha
– sequence: 4
  givenname: Ian D.
  surname: Pavord
  fullname: Pavord, Ian D.
– sequence: 5
  givenname: Timothy C.
  orcidid: 0000-0002-1417-9019
  surname: Hardman
  fullname: Hardman, Timothy C.
– sequence: 6
  givenname: Joseph R.
  surname: Arron
  fullname: Arron, Joseph R.
– sequence: 7
  givenname: Peter
  surname: Bradding
  fullname: Bradding, Peter
– sequence: 8
  givenname: Christopher E.
  surname: Brightling
  fullname: Brightling, Christopher E.
– sequence: 9
  givenname: David F.
  surname: Choy
  fullname: Choy, David F.
– sequence: 10
  givenname: Douglas C.
  surname: Cowan
  fullname: Cowan, Douglas C.
– sequence: 11
  givenname: Ratko
  surname: Djukanovic
  fullname: Djukanovic, Ratko
– sequence: 12
  givenname: Catherine E.
  surname: Hanratty
  fullname: Hanratty, Catherine E.
– sequence: 13
  givenname: Tim W.
  surname: Harrison
  fullname: Harrison, Tim W.
– sequence: 14
  givenname: Cecile T.
  surname: Holweg
  fullname: Holweg, Cecile T.
– sequence: 15
  givenname: Peter H.
  orcidid: 0000-0003-0619-7927
  surname: Howarth
  fullname: Howarth, Peter H.
– sequence: 16
  givenname: Stephen J.
  orcidid: 0000-0002-4524-1663
  surname: Fowler
  fullname: Fowler, Stephen J.
– sequence: 17
  givenname: James L.
  surname: Lordan
  fullname: Lordan, James L.
– sequence: 18
  givenname: Adel H.
  orcidid: 0000-0002-8615-8778
  surname: Mansur
  fullname: Mansur, Adel H.
– sequence: 19
  givenname: Andrew
  surname: Menzies-Gow
  fullname: Menzies-Gow, Andrew
– sequence: 20
  givenname: Robert M.
  surname: Niven
  fullname: Niven, Robert M.
– sequence: 21
  givenname: Douglas S.
  surname: Robinson
  fullname: Robinson, Douglas S.
– sequence: 22
  givenname: Samantha M.
  surname: Walker
  fullname: Walker, Samantha M.
– sequence: 23
  givenname: Ashley
  surname: Woodcock
  fullname: Woodcock, Ashley
– sequence: 24
  givenname: Liam G.
  surname: Heaney
  fullname: Heaney, Liam G.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34561291$$D View this record in MEDLINE/PubMed
BookMark eNp9Uctu1DAUtVArOn18ARLKkk3KdfxIvEFCFQWkSmzo2nLsm45RYg-2ZxB_j8O0FbBgY0v3PO7VOefkJMSAhLyicE3pwN5SphQDYNcAvRzaDjr6gmzWabuOT8gGFLCWKibPyHnO3wCo5Iy-JGeMC0k7RTfE3RpbYsqNmSa0xYeHxrgtJgwWmx--bJuS0JQFQ6nAwdepD41p7OyDt2ausK9vnJqdKb6y8lGV8VBNGpPLdjGX5HQyc8arx_-C3N9--Hrzqb378vHzzfu71nIQpXVDp8zIpROTQylkb63jXFBuDePUsn6EQTI-DghKjKJTk6Osdw4kRcvtwC7Iu6Pvbj8u6Gw9J5lZ75JfTPqpo_H6byT4rX6IB61qeHxg1eDNo0GK3_eYi158tjjPJmDcZ92JXkrBoYNKff3nruclT9FWAjsSbIo5J5yeKRT0WqB-KlD_LlCvBVaV-kdlfanJxvVgP_9X-wvlL6CZ
CitedBy_id crossref_primary_10_1038_s41533_024_00391_w
crossref_primary_10_3390_app12199890
crossref_primary_10_1016_j_jaip_2022_01_027
crossref_primary_10_1080_24745332_2023_2254283
crossref_primary_10_1016_j_anai_2023_12_023
crossref_primary_10_17925_USRPD_2022_7_2_44
crossref_primary_10_1111_cea_14131
crossref_primary_10_1055_a_1918_8517
crossref_primary_10_1183_13993003_00660_2022
Cites_doi 10.1016/j.jaip.2018.01.025
10.1136/thoraxjnl-2015-207630
10.1136/thoraxjnl-2018-212709
10.1007/s40266-014-0153-9
10.1124/mi.11.2.8
10.1001/archinte.162.15.1761
10.1183/09031936.00075614
10.1186/s12931-018-0742-y
10.1186/s13063-017-2384-7
10.1080/13557850303554
10.1164/rccm.200711-1754OC
10.2147/JAA.S176026
10.1016/S2213-2600(20)30397-0
10.1016/S0140-6736(05)17785-X
10.1016/S0140-6736(17)30879-6
10.1164/rccm.201904-0903SO
10.1016/j.rmed.2020.106156
10.1038/clpt.2014.59
10.1016/j.healthpol.2005.07.022
10.1016/S2213-2600(20)30389-1
ContentType Journal Article
Copyright Copyright ©The authors 2022.
Copyright ©The authors 2022. 2022
Copyright_xml – notice: Copyright ©The authors 2022.
– notice: Copyright ©The authors 2022. 2022
CorporateAuthor investigators for the MRC Refractory Asthma Stratification Programme
CorporateAuthor_xml – name: investigators for the MRC Refractory Asthma Stratification Programme
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1183/13993003.00768-2021
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1399-3003
ExternalDocumentID PMC9202483
34561291
10_1183_13993003_00768_2021
Genre Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Medical Research Council
  grantid: MR/M016579/1
– fundername: ;
  grantid: MR/M016579/1
GroupedDBID ---
.55
.GJ
18M
1OC
2WC
31~
3O-
53G
5GY
5RE
5VS
8-1
AAFWJ
AAYXX
AAZMJ
ABCQX
ABJNI
ABOCM
ABSQV
ACEMG
ACGFO
ACPRK
ACXQS
ADBBV
ADDZX
ADMOG
ADYFA
AENEX
AFFNX
AFHIN
AFZJQ
AIZTS
AJAOE
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CAG
CITATION
COF
CS3
DIK
E3Z
EBS
EJD
F5P
F9R
GX1
H13
INIJC
J5H
KQ8
L7B
LH4
LW6
OK1
P2P
PQQKQ
R0Z
RHI
TER
TR2
W8F
WOQ
X7M
ZE2
ZGI
ZXP
~02
AADJU
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c405t-d829ab46d5fde6567ccd44514ca341c37b08634b8e095b529fd137dd061ec4c83
ISSN 0903-1936
1399-3003
IngestDate Thu Aug 21 18:21:46 EDT 2025
Fri Sep 05 13:44:57 EDT 2025
Sat May 31 02:10:31 EDT 2025
Mon Sep 08 01:41:27 EDT 2025
Thu Apr 24 23:05:03 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License Copyright ©The authors 2022.
This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c405t-d829ab46d5fde6567ccd44514ca341c37b08634b8e095b529fd137dd061ec4c83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-0619-7927
0000-0002-1417-9019
0000-0002-4524-1663
0000-0002-8615-8778
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC9202483
PMID 34561291
PQID 2576654020
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9202483
proquest_miscellaneous_2576654020
pubmed_primary_34561291
crossref_primary_10_1183_13993003_00768_2021
crossref_citationtrail_10_1183_13993003_00768_2021
PublicationCentury 2000
PublicationDate 2022-04-01
PublicationDateYYYYMMDD 2022-04-01
PublicationDate_xml – month: 04
  year: 2022
  text: 2022-04-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The European respiratory journal
PublicationTitleAlternate Eur Respir J
PublicationYear 2022
Publisher European Respiratory Society
Publisher_xml – name: European Respiratory Society
References 2024102102391133000_59.4.2100768.10
Bloechliger (2024102102391133000_59.4.2100768.19) 2018; 19
2024102102391133000_59.4.2100768.21
Busby (2024102102391133000_59.4.2100768.7) 2020; 173
2024102102391133000_59.4.2100768.11
2024102102391133000_59.4.2100768.20
2024102102391133000_59.4.2100768.14
2024102102391133000_59.4.2100768.12
2024102102391133000_59.4.2100768.13
Price (2024102102391133000_59.4.2100768.18) 2018; 11
2024102102391133000_59.4.2100768.16
2024102102391133000_59.4.2100768.17
2024102102391133000_59.4.2100768.2
2024102102391133000_59.4.2100768.1
Heaney (2024102102391133000_59.4.2100768.5) 2021; 9
Hanratty (2024102102391133000_59.4.2100768.6) 2018; 19
Bleecker (2024102102391133000_59.4.2100768.3) 2020; 201
2024102102391133000_59.4.2100768.9
2024102102391133000_59.4.2100768.8
Lee (2024102102391133000_59.4.2100768.15) 2021; 9
Heffler (2024102102391133000_59.4.2100768.4) 2018; 6
References_xml – volume: 6
  start-page: 776
  year: 2018
  ident: 2024102102391133000_59.4.2100768.4
  article-title: Inhaled corticosteroids safety and adverse effects in patients with asthma
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2018.01.025
– ident: 2024102102391133000_59.4.2100768.2
  doi: 10.1136/thoraxjnl-2015-207630
– ident: 2024102102391133000_59.4.2100768.8
  doi: 10.1136/thoraxjnl-2018-212709
– ident: 2024102102391133000_59.4.2100768.20
  doi: 10.1007/s40266-014-0153-9
– ident: 2024102102391133000_59.4.2100768.10
  doi: 10.1124/mi.11.2.8
– ident: 2024102102391133000_59.4.2100768.14
  doi: 10.1001/archinte.162.15.1761
– ident: 2024102102391133000_59.4.2100768.17
  doi: 10.1183/09031936.00075614
– volume: 19
  start-page: 75
  year: 2018
  ident: 2024102102391133000_59.4.2100768.19
  article-title: Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis
  publication-title: Respir Res
  doi: 10.1186/s12931-018-0742-y
– ident: 2024102102391133000_59.4.2100768.1
– volume: 19
  start-page: 5
  year: 2018
  ident: 2024102102391133000_59.4.2100768.6
  article-title: A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
  publication-title: Trials
  doi: 10.1186/s13063-017-2384-7
– ident: 2024102102391133000_59.4.2100768.13
  doi: 10.1080/13557850303554
– ident: 2024102102391133000_59.4.2100768.21
  doi: 10.1164/rccm.200711-1754OC
– volume: 11
  start-page: 193
  year: 2018
  ident: 2024102102391133000_59.4.2100768.18
  article-title: Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study
  publication-title: J Asthma Allergy
  doi: 10.2147/JAA.S176026
– volume: 9
  start-page: 57
  year: 2021
  ident: 2024102102391133000_59.4.2100768.5
  article-title: Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(20)30397-0
– ident: 2024102102391133000_59.4.2100768.11
  doi: 10.1016/S0140-6736(05)17785-X
– ident: 2024102102391133000_59.4.2100768.16
  doi: 10.1016/S0140-6736(17)30879-6
– volume: 201
  start-page: 276
  year: 2020
  ident: 2024102102391133000_59.4.2100768.3
  article-title: Systematic literature review of systemic corticosteroid use for asthma management
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201904-0903SO
– volume: 173
  start-page: 106156
  year: 2020
  ident: 2024102102391133000_59.4.2100768.7
  article-title: The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: a systematic review and meta-analysis
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2020.106156
– ident: 2024102102391133000_59.4.2100768.9
  doi: 10.1038/clpt.2014.59
– ident: 2024102102391133000_59.4.2100768.12
  doi: 10.1016/j.healthpol.2005.07.022
– volume: 9
  start-page: 69
  year: 2021
  ident: 2024102102391133000_59.4.2100768.15
  article-title: Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(20)30389-1
SSID ssj0016431
Score 2.4557486
Snippet Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease...
Belonging to a minority ethnic group, multiple prior medication changes, being treated at a specific clinical centre, introduction of systemic corticosteroids...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2100768
SubjectTerms Adrenal Cortex Hormones - therapeutic use
Asthma - drug therapy
Ethnicity
Humans
Minority Groups
Original s
Single-Blind Method
Title Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
URI https://www.ncbi.nlm.nih.gov/pubmed/34561291
https://www.proquest.com/docview/2576654020
https://pubmed.ncbi.nlm.nih.gov/PMC9202483
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagSFUvqOxDARmJIylJ7EycY1WoClIRoFbqLYqXKFMgU7UZDvz6vmc7jocWBBwmGiVeovm-sd9uQl5lJp9rITkoOa1MuM6ypOGyTVKpTVPkWmQp5g4ffZwfnvAPp8XpZNC32SWD3FU_b8wr-R9U4R7gilmy_4BsGBRuwHfAF66AMFz_CuMDf1hOY4MybLqh7nzdWGdgncLINS4JaN2IsiHdkR0Y8-yqq_pUN9gsDboVLofOr9pnE6eC-f4ictLHb2tzI3zBzjjQNz5Z3MbrhFO99rtmpbuVy3n_Yr52Yav41PzwsffvYca3sYkCtNspssW4ZRXEoISlKYvXXV8JfDEZFa4v5wLLSmBv7Lxr3YbAAJdTHQF8_t0izFAazKts2ttCxOH46Da5k5cgZaH7_vPkbwK5LPM1qWDONzfMuEU2xzHWRZhresmv4bWRvHK8Te56RYPuOdbcI7dMf59sHvlQigdEe_LQQB4ayEORBjSQhzry0EVPGzqSh1ry0GVLR_K4Xo481JHnITk5eHe8f5j4IzcSBZL7kGiRV43kc1202oCoXyqlsYQdVw2IO4qVElRgxqUwIJrLIq9anbFSa5AKjeJKsEdko1_25gmhTEJDwThjMKBWlSgNa-EDepLhqSpnJB9_xVr5evR4LMq32uqlgtUjCrVFoUYUZuR16HTuyrH8ufnLEZ4alk30hTW9Wa4ua9Sz5wUaT2bksYMrDDjiPCPlGpChAZZkX3_SLzpbmr3KsUYge_rbMXfI1vQPeUY2houVeQ5i7SBfWEZeAUshof4
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+affecting+adherence+with+treatment+advice+in+a+clinical+trial+of+patients+with+severe+asthma&rft.jtitle=The+European+respiratory+journal&rft.au=Busby%2C+John&rft.au=Matthews%2C+John+G&rft.au=Chaudhuri%2C+Rekha&rft.au=Pavord%2C+Ian+D&rft.date=2022-04-01&rft.eissn=1399-3003&rft.volume=59&rft.issue=4&rft_id=info:doi/10.1183%2F13993003.00768-2021&rft_id=info%3Apmid%2F34561291&rft.externalDocID=34561291
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon